The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
The health news update discusses Washington state's abortion pill stockpile as a safeguard, BioAge's successful IPO, a ...
By Arasu Kannagi Basil and Prakhar Srivastava (Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback